Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-01
2011-03-01
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S053000
Reexamination Certificate
active
07897584
ABSTRACT:
The present invention relates to water-soluble taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives, and in particular to paclitaxel and docetaxel, useful for the preparation of pharmaceutical compositions to be used in the field of oncology, in the treatment of autoimmune disorders and of restenoisis. The invention also relates to the process for preparing taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives by direct synthesis between molecules of hyaluronic acid and of taxane or by indirect synthesis by the introduction of a spacer between the hyaluronic acid or hyaluronic acid derivative and the taxane.
REFERENCES:
patent: 4851521 (1989-07-01), DeLuca et al.
patent: 5502081 (1996-03-01), Kuo et al.
patent: 5648506 (1997-07-01), Desai et al.
patent: 5977163 (1999-11-01), Li et al.
patent: WO9733552 (1997-09-01), None
Luo et al Bioconjugate Chem. 1999, 10, 755-763.
Sparer et al Controlled Release Delivery Systems, Chapter 6, 1983, 107-119.
Luo et al., “Synthesis and Selective Cytotoxicity of a Hyaluronic Acid-Antitumor Bioconjugate”,Bioconjugate Chem, vol. 10, pp. 755-763 (1999).
Sparer et al, “Controlled Release from Glycosaminoglycan Drug Complexes”, Chapter 6, inControlled Release Delivery Systems, New York (1983).
Akima et al., “Evaluation of Antitumor Activities of Hyaluronate Binding Antitumor Drugs: Synthesis, Characterization and Antitumor Activity”, Journal of Drug Targeting, vol. 4, pp. 1-8, 1996.
Denizot et al., “Rapid Colorimetric Assay for Cell Growth and Survival Modifications to the Tetrazolium Dye Procedure Giving Improved Sensitivity and Reliability”, Journal of Immunological Methods, vol. 89, pp. 271-277 (1986).
Andrea Herrera Gayol et al, “Effect of Hyaluronan on Xenotransplanted Breast Cancer”, Experimental and Molecular Pathology, vol. 72, pp. 179-185 (2002).
Luo et al., “A Hyaluronic Acid-Taxol Antitumor Bioconjugate Targeted to Cancer Cells”, Biomacromolecules, vol. 1, pp. 208-218 (2000).
Li et al., “Complete Regression of Well-Established Tumors Using a Novel Water Soluble Poly (L-Glutamic Acid)-Paclitaxel Conjugate”, Cancer Research, vol. 58, pp. 2404-2409, (1998).
Mellado et al., “Preparation and Biological Activity of Taxol Acetates”, Biochemical and Biophysical Research Communications, vol. 124, No. 2, pp. 329-336 (1984).
Huizing et al., “Taxanes: A New Class of Antitumor Agents”, Cancer Investigation, vol. 13, pp. 381-404 (1995).
Manfredi et al., “Taxol Binds to Cellular Microtubules”, The Journal of Cell Biology, vol. 94, pp. 688-696, (1982).
Weiss et al., “Hypersensitivity Reactions From Taxol”, Journal of Clinical Oncology, vol. 8, No. 7, pp. 1263-1268 (1990).
Nuijen et al., “Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes”, Investigational New Drugs, vol. 19, pp. 143-153, (2001).
Robert W. Pfeifer et al., “Precipitation of Paclitaxel During Infusion by Pump”, Am J. Hospital Pharmacology, vol. 50, p. 2518, (1993).
Bettolo Rinaldo Marini
De Luca Gilda
Migneco Luisa Maria
Abelman ,Frayne & Schwab
Fidia Farmaceutici S.p.A.
Jiang Shaojia Anna
Krishnan Ganapathy
LandOfFree
Taxanes covalently bounded to hyaluronic acid or hyaluronic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Taxanes covalently bounded to hyaluronic acid or hyaluronic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Taxanes covalently bounded to hyaluronic acid or hyaluronic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2753652